NextCure, Inc. announced preclinical data for NC605, an anti-Siglec-15 antibody, showing improved bone microarchitecture and reduced fractures in an...

Celcuity Inc. has initiated VIKTORIA-2, a Phase 3 clinical trial investigating gedatolisib combined with a CDK4/6 inhibitor and fulvestrant...

Revolution Medicines announced the publication of research in •Science• detailing the discovery and development of zoldonrasib, a covalent inhibitor...

Unicycive Therapeutics announced positive results from a Phase 2 trial of its investigational phosphate binder, oxylanthanum carbonate (OLC), for...

Alumis, a late-stage biopharmaceutical company, has completed patient enrollment for its Phase 2b LUMUS trial of ESK-001, an oral...

Annexon, Inc. has completed enrollment in its Phase 3 ARCHER II trial for vonaprument, a drug targeting dry age-related...

Quanta Therapeutics appointed Vanessa L. Jacoby as Chief Business Officer and Chief Financial Officer, bringing over 25 years of...

Alzamend Neuro, a clinical-stage biopharmaceutical company developing treatments for Alzheimer’s, bipolar disorder, major depressive disorder, and PTSD, reported positive...

An analysis of genetic and health data from over 700,000 individuals confirms previous estimates of Autosomal Dominant Hypocalcemia type...

Invivyd has appointed Dr. Akiko Iwasaki, a renowned immunobiologist from Yale School of Medicine, to its SPEAR Study Group....